<DOC>
	<DOCNO>NCT02582034</DOCNO>
	<brief_summary>The purpose study determine whether treatment Therasphere optimize efficient compare standard treatment patient suffer hepatocellular carcinoma .</brief_summary>
	<brief_title>Internal Radiation Therapy Hepatocellular Carcinomas With Therasphere : Optimized Dosimetry Versus Standard Dosimetry</brief_title>
	<detailed_description>For patient suffer hepatocellular carcinoma , palliative treatment propose tumor expansion limit liver . One palliative treatment Selective Internal Radiation Therapy ( SIRT ) Therasphere® . This treatment make secure perform diagnostic angiogram couple hepatic perfusion scintigraph patient risk complication identify exclude . The treatment objective , standard dosimetric approach , deliver absorb dose 120 ± 20 Gy treat hepatic volume , often one lobe . Recent retrospective trial show optimize dosimetric approach , consider dose absorbed tumor , technically achievable would probably make possible obtain good effectiveness . In experience , treatment personalisation describe used 60 % patient tumor large 7 cm underlie clinical impact new approach .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Adenoma , Liver Cell</mesh_term>
	<criteria>Age ≥ 18 , Written free inform consent , Histologically demonstrate Hepatocellular Carcinoma ( HCC ) , candidate surgery local ablative treatment ( radio frequency , etc . ) Barcelona Clinic Liver Cancer ( BCLC ) classification A , B C , At least one lesion ≥ 7 cm , Hepatic reserve ( hepatic parenchyma treat ) first SIRT ≥ 30 % , Unilateral involvement , minimal bilateral involvement allow hepatic reserve ≥ 30 % SIRT Child A classification , B bilirubinemia &lt; 35 micromol/L , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , Patients whose biological parameter meet follow criterion : Hemoglobin ≥ 8.5 g/dL , Granulocytes ≥ 1500/mm3 , Platelets ≥ 50,000/mm3 , Bilirubinemia &lt; 35 micromol per liter , Transaminases ≤ five time upper limit normal , Creatininemia ≤ 1.5 time normal upper limit , Expected survival 12 week , Negative pregnancy test woman childbearing age , If sorafenib take diagnostic angiogram must follow least four week stop . HCC operable accessible local ablative treatment ( radio frequency ) , Hepatectomy history unless segmental treatment consider , hepatic reserve ≥ 30 % SIRT , Prior treatment sorafenib unless stop least four week earlier , History chemoembolization principal lesion , except case nodular residual lesion measure least 7 cm case progression initial response , Bilateral disease require whole liver injection hepatic reserve &lt; 30 % SIRT Treatment another cancer less one year earlier , Extrahepatic metastasis adenopathy hilum small 2 cm , &gt; 70 % tumor invasion liver , Bilirubinemia ≥ 35 µmol/L , A Severe underlie biliary pathology : Bile duct anomaly ( stent , dilation ) Cirrhosis biliary origin , Women childbearing age without contraception Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Optimized Dosimetry versus standard Dosimetry</keyword>
	<keyword>Internal Radiation Therapy</keyword>
</DOC>